Reclast (Zoledronic Acid) Safety in Adolescents Ages 12 to 17

This article is pending qualified medical review. It summarizes published evidence and standard practice patterns. It is not a substitute for individualized care from a pediatric endocrinologist or bone specialist.

Zoledronic acid is a nitrogen-containing bisphosphonate given as an intravenous infusion. Under the brand name Reclast, it is FDA-approved for osteoporosis and related bone conditions in adults, given as a 5 mg infusion once yearly. It is not FDA-approved for anyone under 18. When clinicians use it in adolescents aged 12 to 17, that use is off-label, meaning it is prescribed outside the conditions listed on the FDA label based on clinical judgment and a smaller body of pediatric evidence, not a pediatric indication the FDA has reviewed and approved.

Reclast (zoledronic acid) is FDA-approved only for adults; its use in patients aged 12 to 17 for osteogenesis imperfecta, glucocorticoid-induced osteoporosis, or disuse osteoporosis is off-label and rests on small pediatric trials rather than a pediatric indication. A randomized comparison of zoledronic acid against pamidronate in children and adolescents with osteogenesis imperfecta found broadly similar one-year gains in lumbar spine bone mineral density between the two drugs, with an acute post-infusion reaction affecting a substantial share of patients after their first zoledronic acid dose (Barros et al., 2012). Long-term data on growth, reproductive safety, and fracture reduction specific to adolescents remain limited, so decisions about starting, continuing, or stopping therapy require specialist oversight and individualized monitoring rather than adult protocols applied by default.

What is zoledronic acid, and why would a clinician use it off-label in a teenager?

Zoledronic acid binds to bone at sites of active resorption and induces apoptosis in osteoclasts, the cells that break down bone. A single intravenous dose suppresses bone turnover for roughly a year, which is why the adult formulation is dosed annually. In adults, the pivotal trial supporting this use (HORIZON-PFT, published in the New England Journal of Medicine in 2007) reported large reductions in vertebral and hip fracture risk in postmenopausal women over three years. That trial defines the FDA-approved adult indication; it does not include adolescents, and its results should not be assumed to transfer directly to a growing skeleton.

In pediatric bone disease, clinicians reach for zoledronic acid when oral bisphosphonates have failed, are poorly tolerated, or when adherence to weekly or monthly oral dosing is a documented problem. The conditions most often treated this way include osteogenesis imperfecta, glucocorticoid-induced osteoporosis (for example in juvenile idiopathic arthritis or inflammatory bowel disease), and disuse osteoporosis in non-ambulatory adolescents. This is guideline-informed but off-label practice: professional societies including the Endocrine Society address bisphosphonate use in pediatric low bone density in their guidance, but there is no FDA-reviewed pediatric label to point to, and the exact wording of society recommendations should be checked against the current published guideline rather than taken from secondhand summaries.

How does zoledronic acid compare with pamidronate in adolescents?

Pamidronate, given as quarterly infusions, has historically been the more studied intravenous bisphosphonate in pediatric osteogenesis imperfecta. Zoledronic acid's practical appeal is dosing frequency: one infusion a year instead of three or four, which reduces sedation exposure in younger children and missed school time in teens.

A randomized trial by Barros and colleagues (2012) compared annual zoledronic acid with quarterly pamidronate in a small group of children and adolescents with osteogenesis imperfecta and found that lumbar spine bone mineral density gains at one year were similar between the two drugs, without a statistically significant difference favoring either agent (Barros et al., J Pediatr Endocrinol Metab, 2012). The acute-phase reaction was more common after the first zoledronic acid infusion than with pamidronate but became less frequent with repeat dosing, a pattern consistent with adult experience. This trial was small, and its findings should be read as evidence that the two drugs perform comparably on this specific outcome in this population, not as proof of equivalent long-term fracture protection.

A Cochrane systematic review of bisphosphonates for osteogenesis imperfecta in children has examined intravenous versus oral formulations and reported greater spine bone density gains with IV bisphosphonates, while noting that pediatric trials are generally too small and too short to establish confident fracture-rate conclusions (Cochrane Database of Systematic Reviews). Readers relying on this review for a specific number should check the current version, since Cochrane reviews are periodically updated.

What adverse effects have been reported in the 12 to 17 age group?

Acute-phase reaction. A flu-like syndrome, sometimes called the acute-phase reaction, is the most consistently reported early side effect. It typically includes fever, muscle aches, headache, and joint pain, usually peaking at 24 to 48 hours and resolving within about three days. It is most common after the first infusion and less common with subsequent doses. Published pediatric series describe this affecting a large minority to a plurality of first-time recipients; exact rates vary by study and should be confirmed against the specific trial being cited rather than treated as a fixed number. Premedication with acetaminophen around the time of infusion, continued for a day or two afterward, is commonly used to reduce symptom severity.

Hypocalcemia. This is the most clinically important acute risk. Adolescents with osteogenesis imperfecta or those on glucocorticoids may start with marginal calcium and vitamin D stores, which raises risk. Standard practice is to confirm adequate calcium intake and vitamin D status at least two weeks before infusion and to continue supplementation afterward. Specific incidence figures for pediatric hypocalcemia after zoledronic acid vary across sources and require verification against the primary literature before being quoted as a fixed rate.

Renal considerations. Zoledronic acid is renally cleared, and adult prescribing information restricts use at significantly reduced kidney function and requires infusion over no less than 15 minutes to limit renal exposure. Adolescents with a history of kidney stones, a single kidney, or dehydration on the day of infusion typically need postponement or a modified plan. Clinicians should refer to the current FDA label for the exact renal cutoff rather than an older or secondhand figure (FDA prescribing information, verify against the currently active label version).

Osteonecrosis of the jaw (ONJ). ONJ has been reported almost exclusively in adult oncology patients on high-frequency, high-dose zoledronic acid, not the once-yearly osteoporosis dose. It is considered rare at annual dosing, and case reports in adolescents are very uncommon. A dental check before starting therapy and avoiding invasive dental work during active treatment are standard precautions, though the exact incidence figures cited for annual-dose regimens vary between sources and should be checked against a current systematic review before being restated as precise numbers.

Atypical femoral fractures. These are associated with bisphosphonate use exceeding roughly five years in adults and have not been reported in adolescent published series to date. The adult concept of a bisphosphonate "holiday," pausing therapy after several years to reassess risk, has not been formally studied in teenagers. Decisions about stopping or pausing therapy in adolescents are made case by case with specialist input.

Does zoledronic acid affect growth in adolescents?

This is a legitimate and only partly answered question. Bisphosphonates are incorporated into bone during a period when adolescents are actively remodeling and lengthening their skeleton, which is a different physiological setting than treating a postmenopausal adult whose bone turnover is already declining.

Small prospective pediatric case series following adolescents on annual zoledronic acid for several years have generally found height velocity preserved within normal limits for most patients, with occasional reports of transient growth deceleration that normalized over subsequent years. This is reassuring for short courses of therapy but does not fully rule out a subtle effect, particularly with longer treatment durations that have not been well studied. Animal studies at doses well above clinical human exposure have shown growth plate changes; these findings have not been shown to translate into documented growth arrest in published human adolescent data, but the theoretical concern is one reason regulators flag growth monitoring as necessary in pediatric use.

What is established: short courses of annual zoledronic acid in published adolescent series have not shown consistent growth arrest. What is plausible but unproven: subtle, cumulative effects on growth plates with multi-year use that current small studies are underpowered to detect. What is not established: any safe upper limit on treatment duration in adolescents, or long-term skeletal outcomes into adulthood for patients treated as teenagers.

Because of this uncertainty, documenting Tanner stage and tracking height and weight at every visit is standard practice, not an optional extra.

Mental health and the burden of chronic bone disease

Adolescents managing a chronic bone condition carry a real psychological burden that exists independent of the medication itself. Published survey data in adolescents with osteogenesis imperfecta point to elevated rates of anxiety and depressive symptoms compared with peers, though exact prevalence figures differ across studies and should be confirmed against the specific published survey before being cited as a precise statistic.

Annual IV infusion adds a procedural stressor on top of this baseline burden. An acute-phase reaction that is severe or unexpected can make a teenager reluctant to return for the next dose. Structured pre-infusion counseling, covering what symptoms to expect, how long they typically last, and how to manage them, along with a follow-up check-in in the days after infusion, is a reasonable practice used at some pediatric bone clinics to support adherence, though this is a practice pattern rather than a formally trial-tested intervention.

Reproductive safety and contraindications in female adolescents

Bisphosphonates bind to bone and can re-enter circulation years after treatment stops. Zoledronic acid has historically carried an FDA pregnancy risk classification reflecting demonstrated or strongly suspected harm in animal reproductive studies, and it is generally considered incompatible with breastfeeding by drug and lactation reference databases such as LactMed (NIH Bookshelf, LactMed). Readers should confirm the current pregnancy and lactation labeling language directly on the FDA label, since risk category systems and label wording can change.

For a female adolescent, this creates an ongoing counseling obligation, not a one-time conversation. Before each infusion, clinicians typically document that the patient understands the reproductive risk and, if sexually active, has access to reliable contraception. A urine pregnancy test on the day of infusion is standard practice at many centers. Because the drug persists in bone, this counseling point extends well beyond the period of active treatment.

The American College of Obstetricians and Gynecologists does not publish a dedicated bisphosphonate-in-adolescents guideline, but its general approach to teratogenic medications in reproductive-age patients, documented counseling and contraceptive discussion at each relevant visit, applies here (ACOG).

Dosing patterns used in practice

There is no FDA-approved pediatric dose for zoledronic acid in osteoporosis-related indications. Published pediatric protocols have generally used weight-based dosing in the range of roughly 0.025 to 0.05 mg/kg per infusion, capped at 4 to 5 mg, given once yearly. Some centers use the full adult 5 mg annual dose for larger or older adolescents approaching adult body size, based on clinical judgment rather than a validated pediatric weight cutoff. Infusion time and hydration matter: adult labeling requires the infusion be given over no less than 15 minutes, and many pediatric protocols use a slower rate and supplemental IV fluids around the infusion, particularly for patients with any borderline kidney function.

Because none of this is FDA-reviewed pediatric dosing, a family should expect this decision to be made by a pediatric endocrinologist or bone specialist familiar with the published pediatric literature, not extrapolated informally from the adult label.

Monitoring before, during, and between infusions

Before each annual infusion, clinicians typically check serum calcium, phosphate, magnesium, alkaline phosphatase, creatinine, and vitamin D status. Bone density by DXA scan is generally repeated every one to two years. Height and weight are tracked at regular visits during active growth, and pubertal staging is documented periodically. Bone turnover markers are sometimes checked after the first infusion to confirm the drug is suppressing bone turnover as expected, though how much this adds after the first year is debated among specialists.

After a few years of therapy in an adolescent whose underlying condition has stabilized, many bone specialists reassess whether ongoing treatment is still needed. If bone density has normalized and the driving condition (for example, glucocorticoid exposure) is controlled, a monitored pause is a reasonable option to discuss, drawing on the adult bisphosphonate-holiday concept even though this specific approach has not been formally trialed in adolescents.

What does the evidence say about long-term fracture reduction in teens?

The adult fracture-reduction evidence for annual zoledronic acid is strong and comes from a large randomized trial (HORIZON-PFT) with a long-term extension showing continued benefit. The pediatric fracture evidence is much thinner. Retrospective single-center case series in children and adolescents with osteogenesis imperfecta have reported lower clinical fracture rates during treatment compared with the same patients' pre-treatment period, but these studies generally lack a concurrent untreated comparison group, which limits how confidently the fracture reduction can be attributed to the drug rather than to natural history, growth, or other concurrent care changes. Readers who need an exact fracture-reduction percentage for adolescents specifically should treat any such number as unverified until checked against the original published study, since none of the adolescent-specific fracture figures in circulation should be assumed accurate without that check.

Fracture outcomes for adolescents with glucocorticoid-induced osteoporosis on zoledronic acid have not been studied in dedicated randomized trials at all. Current practice in that population extrapolates from adult glucocorticoid-induced osteoporosis trials and the pediatric osteogenesis imperfecta literature, which is a reasonable clinical approach but not the same as direct evidence in that population.

A decision framework for evaluating off-label zoledronic acid in a teenager

This framework is intended to organize a conversation with a pediatric endocrinologist or bone specialist. It is not a substitute for that conversation, and it does not set a dose or diagnose a condition.

Step 1: Is off-label treatment even on the table? Reasonable candidates generally have one of: confirmed osteogenesis imperfecta with a history of fragility fractures, glucocorticoid-induced bone loss with low bone density on DXA, or disuse osteoporosis from immobility, and have already tried or cannot tolerate/adhere to oral bisphosphonate therapy. If none of these apply, the case for reaching for an off-label IV bisphosphonate is weak and other management should be explored first.

Step 2: Are there hard stops?

• Pregnancy, or inability to reliably rule out pregnancy on the day of infusion, in a female with reproductive potential.
• Significantly reduced kidney function (confirm the current threshold against the active FDA label rather than an older figure).
• Uncorrected low calcium or vitamin D status.
• Active, unaddressed dental infection or planned invasive dental work in the near term.

If any of these apply, treatment is paused or reworked, not started as scheduled.

Step 3: What tradeoff is the family actually accepting?

Step 4: What has to happen before the first infusion, and at every one after that?

1. Confirm kidney function is within the range considered safe on the current label.
2. Confirm vitamin D and calcium status are adequate, corrected at least two weeks ahead if not.
3. Complete or update a dental exam.
4. Confirm a negative pregnancy test on infusion day for anyone with reproductive potential.
5. Document Tanner stage, height, and weight for growth tracking.
6. Give the patient and caregiver a written plan for managing the expected post-infusion reaction.
7. Schedule a follow-up contact in the days after infusion to check for problems.

Step 5: When to escalate or reconsider.

• Growth velocity drops off its expected curve after starting treatment.
• Fever after infusion is unusually high, prolonged beyond a few days, or accompanied by symptoms not typical of the acute-phase reaction.
• Kidney function declines between infusions.
• The patient becomes sexually active without reliable contraception.
• Bone density normalizes and the underlying condition is stable, which is the point to discuss whether continued treatment is still justified.

When urgent care is appropriate

A teenager on zoledronic acid should seek urgent evaluation for: fever that is very high or lasts more than a few days after infusion, signs of a low-calcium reaction such as muscle cramps, tingling around the mouth or in the hands, or an irregular heartbeat, a new fracture or sudden new bone pain, or jaw pain or exposed bone following a dental procedure. Any of these warrants contacting the prescribing specialist or seeking urgent medical care rather than waiting for the next scheduled visit.

This article is pending qualified medical review and reflects a summary of published, generally available evidence as of the last review date above. It does not provide individualized dosing or diagnosis. Specific numeric claims drawn from individual pediatric studies are noted where verification against the original publication is recommended before clinical use.